BioSpace News Archive

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named an Arizona Top Workplace of 2022 by AZCentral , the digital home of The Arizona Republic newspaper.

Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors. Dannielle Appelhans is a tenured pharmaceutical executive who has built deep expertise in strategy, manufacturing, supply chain and operations.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.

VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce a multi-year licensing contract of subsidiary Transforming System’s SHREWD Platform and SHREWD Resilience offerings to Buckinghamshire, Oxfordshire and Berkshire Integrated Care System (“BOB ICS”).

Sesen Bio (Nasdaq: SESN ) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum.

Apyx Medical Corporation (NASDAQ: APYX), the manufacturer of Renuvion®, a proprietary helium plasma and radiofrequency technology, announces the receipt of 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the use of Renuvion.

Medsenic, announced today a new publication in Transplantation and Cellular Therapy, - the official Journal of ASTCT (American Society for Transplantation and Cellular Therapy) - that provides insights from its drug Arscimed®, a GMP intravenous formulation of arsenic trioxide, in patients with Chronic Graft Versus Host Disease (cGvHD).

Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data on the sensitivity of its hydroxyl dendrimer-based PET tracer, [18F]OP-801, in comparison to translocator protein 18 kDa [TSPO]-PET, using [18F]GE180 (TSPO-PET), an established PET imaging approach for the detection of neuroinflammation, in a mouse model of Alzheimer’s Disease.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the US and Canada) to evaluate PC14586.

Prometheus Biosciences, Inc. today announced the completion of enrollment for Cohort 1 of the ARTEMIS-UC global Phase 2 study of PRA023 in ulcerative colitis (UC).